DJIA 15,112.19 -206.04 -1.35%
NASDAQ 3,443.20 -38.98 -1.12%
S&P 500 1,628.93 -22.88 -1.39%
market minute promo

Exelixis

NASDAQ: EXEL

4.72 -0.10 (-2.07%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

EXEL $4.72 -2.07%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.80
Previous Close $4.82
Daily Range $4.71 - $4.84
52-Week Range $4.19 - $6.95
Market Cap $867.5M
P/E Ratio -4.92
Dividend (Yield) $0.00 (0.0%)
Volume 1,023,451
Average Daily Volume 1,378,865
Current FY EPS -$1.21

Sector

Healthcare

Industry

Drugs

Exelixis (EXEL) Description

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. Website: http://www.exelixis.com/

News & Commentary

Bullish Two Hundred Day Moving Average Cross - EXEL

Commit To Purchase Exelixis At $2, Earn 10%

Exelixis' Goldman Sachs 34th Annual Global Healthcare Conference - Transcript

Exelixis And Cabozantinib: ASCO 2013 Highlights

Exelixis Announces Webcasts of Upcoming Investor Conference Presentations

Exelixis Presents COMETRIQâ„¢ (cabozantinib) Clinical Trial Data in Patients with Progressive, Metasta

Exelixis Presents Positive COMETRIQ Clinical Trial Data in Patients with Progressive, Metastatic Med

Exelixis Presents Positive COMETRIQ Clinical Trial Data in Patients with Progressive, Metastatic Medullary Thyroid Cancer

Tackling Cancer: Your Best Investing Ideas

Following three months of examining the 12 most-diagnosed cancers, these stocks look like your best investment choices.

Exelixis Present Updated Phase 2 Data for Cabozantinib in Men with Heavily-Pretreated Metastatic Cas

Exelixis Present Updated Phase 2 Data for Cabozantinib in Men with Heavily-Pretreated Metastatic Castration-Resistant Prostate Cancer

New Approvals Spark a Melanoma Drug Battle

The FDA approves two of GlaxoSmithKline's new drugs, adding to a new competitive landscape

See More EXEL News...

EXEL's Top Competitors

EXEL $4.72 (-2.07%)
Current stock: EXEL
LIFE $74.21 (-0.08%)
Current stock: LIFE
WAT $100.22 (-1.65%)
Current stock: WAT
ILMN $70.40 (-1.80%)
Current stock: ILMN